Literature DB >> 16549815

The role of statins in cancer therapy.

Katja Hindler1, Charles S Cleeland, Edgardo Rivera, Charles D Collard.   

Abstract

Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically, statins have been shown to exert several beneficial antineoplastic properties, including decreased tumor growth, angiogenesis, and metastasis. The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16549815     DOI: 10.1634/theoncologist.11-3-306

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  95 in total

1.  High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer.

Authors:  Adam R Wolfe; Rachel L Atkinson; Jay P Reddy; Bisrat G Debeb; Richard Larson; Li Li; Hiroko Masuda; Takae Brewer; Bradley J Atkinson; Abeena Brewster; Naoto T Ueno; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

2.  Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts.

Authors:  Wei Liu; Toni K Choueiri; Eunyoung Cho
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

Review 3.  Omega-3 fatty acids, membrane remodeling and cancer prevention.

Authors:  Natividad R Fuentes; Eunjoo Kim; Yang-Yi Fan; Robert S Chapkin
Journal:  Mol Aspects Med       Date:  2018-04-12

4.  Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

Authors:  Svenja Nölting; Alessio Giubellino; Yasin Tayem; Karen Young; Michael Lauseker; Petra Bullova; Jan Schovanek; Miriam Anver; Stephanie Fliedner; Márta Korbonits; Burkhard Göke; George Vlotides; Ashley Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2014-04-24       Impact factor: 4.736

5.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.

Authors:  Zhongwei Cao; Hua Fan-Minogue; David I Bellovin; Aleksey Yevtodiyenko; Julia Arzeno; Qiwei Yang; Sanjiv Sam Gambhir; Dean W Felsher
Journal:  Cancer Res       Date:  2011-01-24       Impact factor: 12.701

6.  Statins Perturb Gβγ Signaling and Cell Behavior in a Gγ Subtype Dependent Manner.

Authors:  Mithila Tennakoon; Dinesh Kankanamge; Kanishka Senarath; Zehra Fasih; Ajith Karunarathne
Journal:  Mol Pharmacol       Date:  2019-02-14       Impact factor: 4.436

7.  Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis.

Authors:  Martin Michael Peter Schulz; Felix Reisen; Silvana Zgraggen; Stephanie Fischer; Don Yuen; Gyeong Jin Kang; Lu Chen; Gisbert Schneider; Michael Detmar
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

Review 8.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

9.  Nonadherence to Statins and Antihypertensives and Hospitalizations Among Elderly Medicare Beneficiaries With Incident Cancer.

Authors:  Ishveen Chopra; Nilanjana Dwibedi; Malcolm D Mattes; Xi Tan; Patricia Findley; Usha Sambamoorthi
Journal:  J Natl Compr Canc Netw       Date:  2017-11       Impact factor: 11.908

10.  Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells.

Authors:  Benjaporn Buranrat; Wanwisa Suwannaloet; Jarinyaporn Naowaboot
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.